Integrative cancer genomics: models, algorithms and analysis

Abstract

In the past decade, the remarkable development of high-throughput sequencing technology accelerates the generation of large amount of multiple dimensional data such as genomic, epigenomic, transcriptomic and proteomic data. The comprehensive data make it possible to understand the underlying mechanisms of biology and disease such as cancer systematically. It also provides great challenges for computational cancer genomics due to the complexity, scale and noise of data. In this article, we aim to review the recent developments and progresses of computational models, algorithms and analysis of complex data in cancer genomics. These topics of this paper include the identification of driver mutations, the genetic heterogeneity analysis, genomic markers discovery of drug response, pan-cancer scale analysis and so on.

Keywords

cancer genomics / model / algorithm / data integration / bioinformatics / computational biology

References

[1] HanahanD, Weinberg R A. The hallmarks of cancer. Cell, 2000, 100(1): 57–70

[2] HanahanD, Weinberg R A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5): 646–674

[3] The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455(7216): 1061–1068

[4] The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474(7353): 609–615

[5] The International Cancer Genome Consortium. International network of cancer genome projects. Nature, 2010, 464(7291): 993–998

[6] BarretinaJ, Caponigro G, StranskyN , VenkatesanK, Margolin A A, KimS , WilsonC J, Lehár J, KryukovG V , SonkinD, ReddyA, LiuM, Murray L, BergerM F , MonahanJ E, MoraisP, MeltzerJ, Korejwa A, Jané-ValbuenaJ, MapaF A, Thibault J, Bric-FurlongE , RamanP, Shipway A, EngelsI H , ChengJ, YuG K, YuJ, AspesiP Jr, de SilvaM, Jagtap K, JonesM D , WangL, HattonC, PalescandoloE , GuptaS, MahanS, SougnezC, Onofrio R C, LiefeldT , MacConaillL, Winckler W, ReichM , LiN, Mesirov J P, GabrielS B , GetzG, ArdlieK, ChanV, Myer V E, WeberB L , PorterJ, Warmuth M, FinanP , HarrisJ L, Meyerson M, GolubT R , MorrisseyM P, Sellers W R, SchlegelR , GarrawayL A. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 2012, 483(7391): 603–607

[7] GarnettM J, Edelman E J, HeidornS J , GreenmanC D, DasturA, LauK W, Greninger P, ThompsonI R , LuoX, SoaresJ, LiuQ, Iorio F, SurdezD , ChenL, MilanoR J, BignellG R, Tam A T, DaviesH , StevensonJ A, Barthorpe S, LutzS R , KogeraF, Lawrence K, McLaren-DouglasA , MitropoulosX, Mironenko T, ThiH , RichardsonL, ZhouW, JewittF, Zhang T, O’BrienP , BoisvertJ L, PriceS, HurW, Yang W, DengX , ButlerA, ChoiH G, ChangJ W, Baselga J, StamenkovicI , EngelmanJ A, SharmaS V, DelattreO, Saez-Rodriguez J, GrayN S , SettlemanJ, Futreal P A, HaberD A , StrattonM R, Ramaswamy S, McDermottU , BenesC H. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 2012, 483(7391): 570–575

[8] MullighanC, SuX, ZhangJ, Radtke I, PhillipsL A , MillerC B, MaJ, LiuW, Cheng C, SchulmanB A , HarveyR C, ChenI M, CliffordR J , CarrollW L, ReamanG, BowmanW P, Devidas M, GerhardD S , YangW, Relling M V, ShurtleffS A , CampanaD, Borowitz M J, PuiC H , SmithM, HungerS P, WillmanC L, Downing J R, the Children’s Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. The New England Journal of Medicine, 2009, 360(5): 470–480

[9] StrattonM R, Campbell P J, FutrealP A . The cancer genome. Nature, 2009, 458(7239): 719–724

[10] VazquezM, de la Torre V, ValenciaA . Chapter 14: Cancer genome analysis. Plos Computational Biology, 2012, 8(12): e1002824

[11] VogelsteinB, Papadopoulos N, VelculescuV E , ZhouS B, DiazL A, KinzierK W. Cancer genome landscapes. Science, 2013, 339(6127): 1546–1558

[12] WheelerD A, WangL H. From human genome to cancer genome: the first decade. Genome Research, 2013, 23(7): 1054–1062

[13] ZhangJ H, ZhangS H. The discovery of mutated driver pathways in cancer: models and algorithms. 2016, arXiv:1604.01298

[14] LiuZ Q, ZhangS H. Toward a systematic understanding of cancers: a survey of the pan-cancer study. Frontiers in Genetics, 2014, 5: 194

[15] YatesL R, Campbell P J. Evolution of the cancer genome. Nature Reviews Genetics, 2012, 13(11): 795–806

[16] SunY J, YaoJ, NowakN J, Goodison S. Cancer progression modeling using static sample data. Genome Biology, 2014, 15: 440

[17] WangJ G, Khiabanian H, RossiD , FabbriG, GatteiV, ForconiF, Laurenti L, MarascaR , PoetaG D, FoaR, PasqualucciL , GaidanoG, Rabadan R. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. Elife, 2014, 3: e02869

[18] Nik-ZainalS, Van Loo P, WedgeD C , AlexandrovL B, Greenman C D, LauK W , RaineK, JonesD, MarshallJ, Ramakrishna M, ShlienA , CookeS L, HintonJ, MenziesA, Stebbings L A, LeroyC , JiaM, RanceR, MudieL J, Gamble S J, StephensP J , McLarenS, TarpeyP S, PapaemmanuilE , DaviesH R, VarelaI, McBrideD J, Bignell G R, LeungK , ButlerA P, TeagueJ W, MartinS, Jönsson G, MarianiO , BoyaultS, MironP, FatimaA, Langerød A, AparicioS A , TuttA, Sieuwerts A M, BorgA , ThomasG, Salomon A V, RichardsonA L , Børresen-DaleA L , FutrealP A, Stratton M R, CampbellP J , Breast Cancer Working Group of the International Cancer Genome Consortium. The life history of 21 breast cancers. Cell, 2012, 149(5): 994–1007

[19] LiuZ Q, ZhangX S, ZhangS H. Breast tumor subgroups reveal diverse clinical predictive power. Scientific Reports, 2014, 4: 4002

[20] HofreeM, ShenJ P, CarterH, Gross A, IdekerT . Network-based stratification of tumor mutations. Nature Methods, 2013, 10(11): 1108–1115

[21] LuJ, GetzG, MiskaE A, Alvarez-Saavedra E, LambJ , PeckD, Sweet- Cordero A, EbertB L , MarkR H, Ferrando A A, DowningJ R , JacksT, Horvitz H R, GolubT R . MicroRNA expression profiles classify human cancers. Nature, 2005, 435(7043): 834–838

[22] Reis-FilhoJ S, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet, 2011, 378(9805): 1812–1823

[23] KramerR, CohenD. Functional genomics to new drug targets. Nature Reviews Drug Discovery, 2004, 3(11): 965–972

[24] LambJ, Crawford E D, PeckD , ModellJ W, BlatI C, WrobelM J, Lerner J, BrunetJ P , SubramanianA, RossK N, ReichM, Hieronymus H, WeiG , ArmstrongS A, Haggarty S J, ClemonsP A , WeiR, CarrS A, LanderE S, Golub T R. The Connectivity Map: using geneexpression signatures to connect small molecules, genes, and disease. Science, 2006, 313(5795): 1929–1935

[25] BansalM, YangJ, KaranC, Menden M P, CostelloJ C , TangH, XiaoG, LiY, AllenJ, ZhongR, Chen B, KimM , WangT, HeiserL M, RealubitR, Mattioli M, AlvarezM J , ShenY, NCI-DREAM Community, GallahanD , SingerD, Saez-Rodriguez J, XieY , StolovitzkyG, Califano A, NCI-DREAM Community. A community computational challenge to predict the activity of pairs of compounds. Nature Biotechnology, 2014, 32(12): 1213–1222

[26] CirielloG, MillerM L, AksoyB A, Senbabaoglu Y, SchultzN , SanderC. Emerging landscape of oncogenic signatures across human cancers. Nature Genetics, 2013, 45(10): 1127–1133

[27] KandothC, McLellan M D, VandinF , YeK, NiuB F, LuC, XieM C, ZhangQ Y, McMichael J F, WyczalkowskiM A , LeisersonM D, MillerC A, WelchJ S, Walter M J, WendlM C , LeyT J, WilsonR K, RaphaelB J, Ding L. Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502(7471): 333–339

[28] LawrenceM S, Stojanov P, MermelC H , RobinsonJ T, Garraway L A, GolubT R , MeyersonM, Gabriel S B, LanderE S , GetzG. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 2014, 505(7484): 495–501

[29] ZackT I, Schumacher S E, CarterS L , CherniackA D, Saksena G, TabakB , LawrenceM S, ZhsngC Z, WalaJ, Mermel C H, SougnezC , GabrielS B, Hernandez B, ShenH , LairdP W, GetzG, MeyersonM, Beroukhim R. Pan-cancer patterns of somatic copy number alteration. Nature Genetics, 2013, 45(10): 1134–1140

[30] DingL, GetzG, WheelerD A, Mardis E R, McLellanM D , CibulskisK, Sougnez C, GreulichH , MuznyD M, MorganM B, FultonL, Fulton R S, ZhangQ Y , WendlM C, Lawrence M S, LarsonD E , ChenK, Dooling D J, SaboA , HawesA C, ShenH, JhangianiS N , LewisL R, HallO, ZhuY M, Mathew T, RenY , YaoJ Q, Scherer S E, ClercK , MetcalfG A, NgB, MilosavljevicA , Gonzalez-GarayM L, Osborne J R, MeyerR , ShiX Q, TangY Z, KoboldtD C, Lin L, AbbottR , MinerT L, PohlC, FewellG, Haipek C, SchmidtH , Dunford-ShoreB H, Kraja A, CrosbyS D , SawyerC S, Vickery T, SanderS , RobinsonJ, Winckler W, BaldwinJ , ChirieacL R, DuttA, FennellT, Hanna M, JohnsonB E , OnofrioR C, ThomasR K, TononG, Weir B A, ZhaoX J , ZiaugraL, ZodyM C, GiordanoT, Orringer M B, RothJ A , SpitzM R, Wistuba I I, OzenbergerB , GoodP J, ChangA C, BeerD G, Watson M A, LadanyiM , BroderickS, Yoshizawa A, TravisW D , PaoW, Province M A, WeinstockG M , VarmusH E, Gabriel S B, LanderE S , GibbsR A, Meyerson M, WilsonR K . Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455(7216): 1069–1075

[31] SjöblomT, JonesS, WoodL D, Parsons D W, LinJ , BarberT D, Mandelker D, LearyRJ , PtakJ, Silliman N, SzaboS , BuckhaultsP, Farrell C, MeehP , MarkowitzS D, WillisJ, DawsonD, Willson J K, GazdarA F , HartiganJ, WuL, LiuC S, Parmigiani G, ParkB H , BachmanK E, Papadopoulos N, VogelsteinB , KinzlerK W, Velculescu V E. The consensus coding sequences of human breast and colorectal cancers. Science, 2006, 314(5797): 268–274

[32] StamatoyannopoulosJ A, Adzhubei I, ThurmanR E , KryukovG V, MirkinS M, SunyaevS R. Human mutation rate associated with DNA replication timing. Nature Genetics, 2009, 41(4): 393–395

[33] ChenC L, Rappailles A, DuquenneL , HuvetM, Guilbaud G, FarinelliL , AuditB, d’Aubenton-Carafa Y, ArneodoA , HyrienO, Thermes C. Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Research, 2010, 20(4): 447–457

[34] DeesN D, ZhangQ Y, KandothC, Wendl M C, SchierdingW , KoboldtD C, MooneyT B, CallawayM B , DoolingD, MardisE R, WilsonR K, Ding L. MuSiC: identifying mutational significance in cancer genomes. Genome Research, 2012, 22(8): 1589–1598

[35] LawrenceM S, Stojanov P, PolakP , KryukovG V, Cibulskis K, SivachenkoA , CarterS L, Stewart C, MermelC H , RobertsS A, KiezunA, HammermanP S , McKennaA, DrierY, ZouL, Ramos A H, PughT J , StranskyN, HelmanE, KimJ, Sougnez C, AmbrogioL , NickersonE, Shefler E, CortésM L , AuclairD, Saksena G, VoetD , NobleM, DiCaraD, LinP, Lichtenstein L, HeimanD I , FennellT, Imielinski M, HernandezB , HodisE, BacaS, DulakA M, Lohr J, LandauD A , WuC J, Melendez-Zajgla J, Hidalgo-MirandaA , KorenA, McCarroll S A, MoraJ , LeeR S, Crompton B, OnofrioR , ParkinM, Winckler W, ArdlieK , GabrielS B, Roberts CW, BiegelJ A , StegmaierK, BassA J, GarrawayL A , MeyersonM, GolubT R, GordeninD A , SunyaevS, LanderE S, GetzG. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499(7457): 214–218

[36] YounA, SimonR. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics, 2011, 27(2): 175–181

[37] TamboreroD, Gonzalez-Perez A, Lopez-BigasN . Oncodriveclust: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics, 2013, 29(18): 2238–2244

[38] KorthauerK D, Kendziorski C. MADGiC: a model-based approach for identifying driver genes in cancer. Bioinformatics, 2015, 31(10): 1526–1535

[39] WuG M, FengX, SteinL. A human functional protein interaction network and its application to cancer data analysis. Genome Biology, 2010, 11(5): R53

[40] VandinF, UpfalE, RaphaelB J. Algorithms for detecting significantly mutated pathways in cancer. Journal of Computational Biology, 2011, 18(3): 507–522

[41] LeisersonM D M, VandinF, WuH T, Dobson J R, EldridgeJ V , ThomasJ L, Papoutsaki A, KimY , NiuB F, McLellan M, LawrenceM S , Gonzalez-PerezA, Tamborero D, ChengY W , RyslikG A, Lopez-Bigas N, GetzG , DingL, Raphael B J. Pan-cancer network analysisidentifies combinations of rare somatic mutations across pathways and protein complexes. Nature Genetics, 2015, 47(2): 106–114

[42] CeramiE, DemirE, SchultzN, Taylor B S, SanderC . Automated network analysis identifies core pathways in glioblastoma. Plos One, 2010, 5(2): e8918

[43] YeangC H, McCormick F, LevineA . Combinatorial patterns of somatic gene mutations in cancer. The FASEB Journal, 2008, 22(8): 2605–2622

[44] VandinF, UpfalE, RaphaelB J. De novo discovery of mutated driver pathways in cancer. Genome Research, 2012, 22(2): 375–385

[45] ZhaoJ F, ZhangS H, WuL Y, Zhang X S. Efficient methods for identifying mutated driver pathways in cancer. Bioinformatics, 2012, 28(22): 2940–2947

[46] ZhangJ F, ZhangS H, WangY, Zhang X S. Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data. BMC Systems Biology, 2013, 7(Suppl 2): S4

[47] ZhangJ H, WuL Y, ZhangX S, Zhang S H. Discovery of co-occurring driver pathways in cancer. BMC Bioinformatics, 2014, 15: 271

[48] LeisersonM D, BlokhD, SharanR, Raphael B J. Simultaneous identification of multiple driver pathways in cancer. Plos Computational Biology, 2013, 9(5): e1003054

[49] AndersonK, LutzC, van DelftF W , BatemanC M, GuoY, ColmanS M, Kempski H, MoormanA V , TitleyI, Swansbury J, KearneyL , EnverT, Greaves M. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature, 2011, 469(7330): 356–361

[50] CampbellP J, Yachida S, MudieL J , StephensP J, Pleasance E D, StebbingsL A , MorsbergerL A, Latimer C, McLarenS , LinM L, McBride D J, VarelaI , Nik-ZainalS A, LeroyC, JiaM, Menzies A, ButlerA P , TeagueJ W, Griffin C A, BurtonJ , SwerdlowH, QuailM A, StrattonM R , Iacobuzio-DonahueC, Futreal P A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 2010, 467(7319): 1109–1113

[51] WalterM J, ShenD, DingL, Shao J, KoboldtD C , ChenK, LarsonD E, McLellanM D , DoolingD, AbbottR, FultonR, Magrini V, SchmidtH , Kalicki-VeizerJ, O’Laughlin M, FanX , GrillotM, Witowski S, HeathS , FraterJ L, EadesW, TomassonM, Westervelt P, DiPersioJ F , LinkD C, MardisE R, LeyT J, Wilson R K, GraubertT A . Clonal architecture of secondary acute myeloid leukemia. The New England Journal of Medicine, 2012, 366(12): 1090–1098

[52] WuX C, Northcott P A, DubucA , DupuyA J, ShihD J, WittH, Croul S, BouffetE , FultsD W, Eberhart C G, GarziaL , Van MeterT, ZagzagD, JabadoN, Schwartzentruber J, MajewskiJ , ScheetzT E, Pfister S M, KorshunovA , LiX N, Scherer SW, ChoY J , AkagiK, MacDonald T J, KosterJ , McCabeM G, SarverA L, CollinsV P, Weiss W A, LargaespadaD A , CollierL S, TaylorM D. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature, 2012, 482(7386): 529–533

[53] QiaoY, Quinlan A R, JazaeriA A , VerhaakR G, Wheeler D A, MarthG T . SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biology, 2014, 15(8): 443

[54] RothA, Khattra J, YapD , WanA, LaksE, BieleJ, Ha G, AparicioS , Bouchard-CôtéA , ShahS P. PyClone: statistical inference of clonal population structure in cancer. Nature Methods, 2014, 11(4): 396–398

[55] XiaH, LiuY N, WangM H, Li A. Identification of genomic aberrations in cancer subclones from heterogeneous tumor samples. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2015, 12(3): 679–685

[56] FischerA, Vázquez-García I, IllingworthC J , MustonenV. Highdefinition reconstruction of clonal composition in cancer. Cell Reports, 2014, 7(5): 1740–1752

[57] LeeJ, Mueller P, SenguptaS , GulukotaK, JiY. Bayesian inference for tumor subclones accounting for sequencing and structural variant. 2014, arXiv:1409.7158

[58] NavinN, Kendall J, TrogeJ , AndrewsP, Rodgers L, McIndooJ , CookK, Stepansky A, LevyD , EspositoD, Muthuswamy L, KrasnitzA , McCombieW R, HicksJ, WiglerM. Tumour evolution inferred by single-cell sequencing. Nature, 2011, 472(7341): 90–94

[59] HouY, SongL T, ZhuP, Zhang B, TaoY , XuX, LiF Q, WuK, LiangJ, ShaoD, Wu H J, YeX F , YeC, WuR H, JianM, Chen Y, XieW , ZhangR R, ChenL, LiuX, Yao X T, ZhengH C , YuC, LiQ B, GongZ L, Mao M, YangX , YangL, LiJ X, WangW, Lu Z H, GuN , LaurieG, BolundL, KristiansenK , WangJ, YangH M, LiY R, Zhang X Q, WangJ . Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell, 2012, 148(5): 873–885

[60] XuX, HouY, YinX Y, Bao L, TangA F , SongL T, LiF Q, TsangS, Wu K, WuH J , HeW M, ZengL, XingM J, Wu R H, JiangH , LiuX, CaoD D, GuoG W, Hu X D, GuiY T , LiZ, XieW Y, SunX J, Shi M, CaiZ M , WangB, ZhongM M, LiJ X, Lu Z H, GuN , ZhangX Q, Goodman L, BolundL , WangJ, YangH M, KristiansenK , DeanM, LiY R, WangJ. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell, 2012, 148(5): 886–895

[61] MooreM J. From birth to death: the complex lives of eukaryotic mRNAs. Science, 2005, 309(5740): 1514–1518

[62] ChuangH, HofreeM, IdekerT. A decade of systems biology. Annual Reviews Cell and Developmental Biology, 2010, 26: 721–744

[63] OrphanidesG, Reinberg D. A unified theory of gene expression. Cell, 2002, 108(4): 439–451

[64] JaenischR, BirdA. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genetics, 2003, 33: 245–254

[65] ZhangW, ZhuJ, SchadtE E, Liu J S. A bayesian partition method for detecting pleiotropic and epistatic eQTL modules. Plos Computational Biology, 2010, 6(1): e1000642

[66] MankooP K, ShenR, SchultzN, Levine D A, SanderC . Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. Plos One, 2011, 6(11): e24709

[67] KutalikZ, Beckmann J S, BergmannS . A modular approach for integrative analysis of large-scale gene-expression and drug-response data. Nature Biotechnology, 2008, 26(5): 531–539

[68] ChenJ Y, ZhangS H. Integrative analysis for identifying joint modular patterns of gene-expression and drug-response data. Bioinformatics, 2016, 32(11): 1724–1732

[69] WittenD M, Tibshirani R J. Extensions of sparse canonical correlation analysis with applications to genomic data. Statistical Applications in Genetics and Molecular Biology, 2009, 8(1): 1–27

[70] ChenK, ChanK S, StensethN C . Reduced rank stochastic regression with a sparse singular value decomposition. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 2012, 74(2): 203–221

[71] MaX, XiaoL, WongW H. Learning regulatory programs by threshold SVD regression. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(44): 15675–15680

[72] ZhangS H, LiuC C, LiW Y, Shen H, LairdP W , ZhouX J. Discovery of multi-dimensional modules by integrative analysis of cancer genomic data. Nucleic Acids Research, 2012, 40(19): 9379–9391

[73] ZhangS H, LiQ J, LiuJ, Zhou X J. A novel computational framework for simultaneous integration of multiple types of genomic data to identify microRNA-gene regulatory modules. Bioinformatics, 2011, 27(13): 401–409

[74] ZitnikM, ZupanB. Data fusion by matrix factorization. IEEE Transactions on Pattern Analysis & Machine Intelligence, 2015, 37(1): 41–53

[75] LiW Y, ZhangS H, LiuC C, Zhou X J. Identifying multi-layer gene regulatory modules from multi-dimensional genomic data. Bioinformatics, 2012, 28(19): 2458–2466

[76] KonstantinopoulosP A, Spentzos D, CannistraS A . Gene-expression profiling in epithelial ovarian cancer. Nature Clinical Practice Oncology, 2008, 5(10): 577–587

[77] CareyL A, PerouC M, LivasyC A, Dressler L G, CowanD , ConwayK, KaracaG, TroesterM A , TseC K, Edmiston S, DemingS L , GeradtsJ, CheangM C, NielsenT O, Moorman P G, EarpH S , MillikanR C. Race, breast cancer subtypes, and survival in the carolina breast cancer study. The Journal of the American Medical Association, 2006, 295(21): 2492–2502

[78] KonstantinopoulosP A, Spentzos D, KarlanB Y , TaniguchiT, Fountzilas E, FrancoeurN , LevineD A, Cannistra S A. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. Journal of Clinical Oncology, 2010, 28(22): 3555–3561

[79] VerhaakR G, Hoadley K A, PurdomE , WangV, QiY, WilkersonM D , MillerC R, DingL, GolubT, Mesirov J P, AlexeG , LawrenceM, O’Kelly M, TamayoP , WeirB A, Gabriel S, WincklerW , GuptaS, Jakkula L, FeilerH S , HodgsonJ G, JamesC D, SarkariaJ N , BrennanC, KahnA, SpellmanP T , WilsonR K, SpeedT P, GrayJ W, Meyerson M, GetzG , PerouC M, HayesD N, Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17(1): 98–110

[80] LiuZ Q, ZhangS H. Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features. BMC Genomics, 2015, 16: 503

[81] CurtisC, ShahS P, ChinS F, Turashvili G, RuedaO M , DunningM J, SpeedD, LynchA G, Samarajiwa S, YuanY , GräfS, HaG, HaffariG, Bashashati A, RussellR , McKinneyS; METABRIC Group, LangerødA , GreenA, Provenzano E, WishartG , PinderS, WatsonP, MarkowetzF, Murphy L, EllisI , PurushothamA, Børresen-Dale A L, BrentonJ D , TavaréS, CaldasC, AparicioS. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 2012, 486(7403): 346–352

[82] ParkerJ S, Mullins M, CheangM C , LeungS, VoducD, VickeryT, Davies S, FauronC , HeX, HuZ, QuackenbushJ F , StijlemanI J, Palazzo J, MarronJ S , NobelA B, MardisE, NielsenT O, Ellis M J, PerouC M , BernardP S. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology, 2009, 27(8): 1160–1167

[83] ShoemakerR H. The NCI60 human tumor cell line screen. Nature Reviews Cancer, 2006, 6: 813–823

[84] EduatiF, Mangravite L M, WangT , TangH, BareJ C, HuangR, Norman T, KellenM , MendenM P, YangJ C, ZhanX W, Zhong R, XiaoG H , XiaM H, AbdoN, KosykO, NIEHS-NCATS-UNC DREAM Toxicogenetics Collaboration, FriendS, DearryA, SimeonovA, Tice R R, RusynI , WrightF A, Stolovitzky G, XieY , Saez-RodriguezJ. Prediction of human population responses to toxic compounds by a collaborative competition. Nature Biotechnology, 2015, 33(9): 933–940

[85] ZhaoJ, ZhangX S, ZhangS H. Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs. CPT: Pharmacometrics & Systems Pharmacology, 2014, 3(2): 1–7

[86] The Cancer Genome Atlas Research Network, WeinsteinJ N , CollissonE A, MillsG B, ShawK R, Ozenberger B A, EllrottK , ShmulevichI, SanderC, StuartJ M. The cancer genome atlas pan-cancer analysis project. Nature Genetics, 2013, 45(10): 1113–1120

[87] ReimandJ, WagihO, BaderG D.The mutational landscape of phosphorylation signaling in cancer. Scientific Reports, 2013, 3: 2651

[88] WitteT, PlassC, GerhauserC. Pan-cancer patterns of DNA methylation. Genome Medicine, 2014, 6(8): 66

[89] GevaertO, Tibshirani R, PlevritisS K . Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome Biology, 2015, 16: 17

[90] YangX F, ShaoX J, GaoL, Zhang S H. Systematic DNA methylation analysis of multiple cell lines reveals common and specific patterns within and across tissues of origin. Human Molecular Genetics, 2015, 24(15): 4374–4384

[91] YangX F, ShaoX J, GaoL, Zhang S H. Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Briefings in Bioinformatics, 2016, doi:10.1093/bib/bbw063

RIGHTS & PERMISSIONS

2016 Higher Education Press and Springer-Verlag Berlin Heidelberg